Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database

详细信息    查看全文

• 作者：Manfred Hauben ; Eric Y. Hung ; Kelly C. Hanretta ; Sripal Bangalore…
• 刊名：Drug Safety
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：38
• 期：11
• 页码：1127-1139
• 全文大小：499 KB
• 参考文献：1.Crouse LJ, Cheirif J, Hanly DE, Kisslo JA, Labovitz AJ, Raichlen JS, Schutz RW, Shah PM, Smith MD. Opacification and border delineation improvement in patients with suboptimal endocardial border definition in routine echocardiography: results of the Phase III Albunex Multicenter Trial. J Am Coll Cardiol. 1993;22(5):1494鈥?00.CrossRef PubMed
  2.Reilly JP, Tunick PA, Timmermans RJ, Stein B, Rosenzweig BP, Kronzon I. Contrast echocardiography clarifies uninterpretable wall motion in intensive care unit patients. J Am Coll Cardiol. 2000;35(2):485鈥?0.CrossRef PubMed
  3.US Food and Drug Administration, revised prescribing information for Definity on August 2011. http://鈥媤ww.鈥媋ccessdata.鈥媐da.鈥媑ov/鈥媎rugsatfda_鈥媎ocs/鈥媗abel/鈥?011/鈥?21064s011lbl.鈥媝df . Accessed 3 Jun 2015.
  4.US Food and Drug Administration, revised prescribing information for Optison on August 17, 2012. http://鈥媤ww.鈥媋ccessdata.鈥媐da.鈥媑ov/鈥媎rugsatfda_鈥媎ocs/鈥媗abel/鈥?012/鈥?20899s015lbl.鈥媝df . Accessed 3 Jun 2015.
  5.Yu EH, Sloggett CE, Iwanochko RM, Rakowski H, Siu SC. Feasibility and accuracy of left ventricular volumes and ejection fraction determination by fundamental, tissue harmonic, and intravenous contrast imaging in difficult-to-image patients. J Am Soc Echocardiogr. 2000;13(3):216鈥?4.CrossRef PubMed
  6.Malm S, Frigstad S, Sagberg E, Larsson H, Skjaerpe T. Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiography: a comparison with magnetic resonance imaging. J Am Coll Cardiol. 2004;44(5):1030鈥?.CrossRef PubMed
  7.U.S. Food and Drug Administration Alert. Micro-bubble contrast agents (marketed as Definity (Perflutren Lipid Microsphere) Injectable Suspension and Optison (Perflutren Protein-Type A Microspheres for Injection). 2007. http://鈥媤ww.鈥媐da.鈥媑ov/鈥婼afety/鈥婱edWatch/鈥婼afetyInformatio鈥媙/鈥婼afetyAlertsforH鈥媢manMedicalProdu鈥媍ts/鈥媢cm152686.鈥媓tm . Accessed 3 Jun 2015.
  8.US Food and Drug Administration, FDA Advisory Committee Briefing Document, Cardiovascular and Renal Drugs Advisory Committee June 24, 2008, Safety considerations in the development of ultrasound contrast agents. http://鈥媤ww.鈥媐da.鈥媑ov/鈥媜hrms/鈥媎ockets/鈥媋c/鈥?8/鈥媌riefing/鈥?008-4369b1-01.鈥媝df . Accessed 3 Jun 2015.
  9.Main ML, Goldman JH, Grayburn PA. Ultrasound contrast agents: balancing safety versus efficacy. Exp Opin Drug Saf. 2009;8(1):49鈥?6.CrossRef
  10.Smyth YM, Gabriel RS, Sabik EM, Klein AL, Grimm R, Thomas JD, Menon V. Marked decline in clinical use of ultrasound contrast agents following black box warning: observations from the clinic. Eur Heart J. 2008;29:376.
  11.Summary Minutes of May 2, 2011 Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees. http://鈥媤ww.鈥媐da.鈥媑ov/鈥媎ownloads/鈥婣dvisoryCommitte鈥媏s/鈥婥ommitteesMeetin鈥媑Materials/鈥婦rugs/鈥婥ardiovascularan鈥媎RenalDrugsAdvis鈥媜ryCommittee/鈥婾CM255248.鈥媝df . Accessed 3 Jun 2015.
  12.Weiss RJ, Ahmad M, Villanueva F, Schmitz S, Bhat G, Hibberd MG, Main ML. CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice. J Am Soc Echocardiogr. 2012;25(7):790鈥?.CrossRef PubMed
  13.Wei K, Main ML, Lang RM, Klein A, Angeli S, Panetta C, Mikati I, Lee LV, Bernstein JA, Ahmad M. The effect of definity on systemic and pulmonary hemodynamics in patients. J Am Soc Echocardiogr. 2012;25(5):584鈥?.CrossRef PubMed
  14.Exuzides A, Main ML, Colby C, Grayburn PA, Feinstein SB, Goldman JH. A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without ultrasound contrast. JACC Cardiovasc Imaging. 2010;3(6):578鈥?5.CrossRef PubMed
  15.Dolan MS, Gala SS, Dodla S, Abdelmoneim SS, Xie F, Cloutier D, Bierig M, Mulvagh SL, Porter TR, Labovitz AJ. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience. J Am Coll Cardiol. 2009;53(1):32鈥?.CrossRef PubMed
  16.Gabriel RS, Smyth YM, Menon V, Klein AL, Grimm RA, Thomas JD, Sabik EM. Safety of ultrasound contrast agents in stress echocardiography. Am J Cardiol. 2008;102(9):1269鈥?2.CrossRef PubMed
  17.Herzog CA. Incidence of adverse events associated with use of perflutren contrast agents for echocardiography. JAMA. 2008;299(17):2023鈥?.CrossRef PubMed
  18.Khawaja OA, Shaikh KA, Al-Mallah MH. Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents. Am J Cardiol. 2010;106(5):742鈥?.CrossRef PubMed
  19.Kusnetzky LL, Khalid A, Khumri TM, Moe TG, Jones PG, Main ML. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies. J Am Coll Cardiol. 2008;51(17):1704鈥?.CrossRef PubMed
  20.Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol. 2008;102(12):1742鈥?.CrossRef PubMed
  21.Wei K, Mulvagh SL, Carson L, et al. The safety of Definity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr. 2008;21(11):1202鈥?.CrossRef PubMed
  22.Aggeli C, Giannopoulos G, Roussakis G, Christoforatou E, Marinos G, Toli C, Pitsavos C, Stefanadis C. Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for detection of ischemia in 5250 studies. Heart. 2008;94(12):1571鈥?.CrossRef PubMed
  23.Platts DG, Luis SA, Roper D, Burstow D, Call T, Forshaw A, Pascoe R. The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort. Heart Lung Circ. 2013;22(12):996鈥?002.CrossRef PubMed
  24.Abdelmoneim SS, Bernier M, Scott CG, Dhoble A, Ness SA, Hagen ME, Moir S, McCully RB, Pellikka PA, Mulvagh SL. Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study. Circ Cardiovasc Imaging. 2010;3(3):240鈥?.CrossRef PubMed
  25.Abdelmoneim SS, Bernier M, Scott CG, Dhoble A, Ness SA, Hagen ME, Moir S, McCully RB, Pellikka PA, Mulvagh SL. Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients. JACC Cardiovasc Imaging. 2009;2(9):1048鈥?6.CrossRef PubMed
  26.Shaikh K, Chang SM, Peterson L, Rosendahl-Garcia K, Quinones MA, Nagueh SF, Kurrelmeyer K, Zoghbi WA. Safety of contrast administration for endocardial enhancement during stress echocardiography compared with noncontrast stress. Am J Cardiol. 2008;102(11):1444鈥?0.CrossRef PubMed
  27.Anantharam B, Chahal N, Chelliah R, Ramzy I, Gani F, Senior R. Safety of contrast in stress echocardiography in stable patients and in patients with suspected acute coronary syndrome but negative 12-hour troponin. Am J Cardiol. 2009;104(1):14鈥?.CrossRef PubMed
  28.Hauben M, Hung EY. A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs. J Clin Pharmacol. 2013;53(7):762鈥?2.CrossRef PubMed
  29.Hauben M, Hung EY. Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield鈥檚 condition. Int J Med Sci. 2013;10(8):965鈥?3.PubMed Central CrossRef PubMed
  30.FDA adverse event reporting system. http://鈥媤ww.鈥媐da.鈥媑ov/鈥媎rugs/鈥媑uidancecomplian鈥媍eregulatoryinfo鈥媟mation/鈥媠urveillance/鈥媋dversedrugeffec鈥媡s/鈥媎efault.鈥媓tm . Accessed 3 Jun 2015.
  31.MedDRA庐 Maintenance and Support Services Organization. Introductory guide for Standardised MedDRA庐 Queries (SMQs) Version 17.0. 2014. http://鈥媤ww.鈥媘eddra.鈥媜rg/鈥媠ites/鈥媎efault/鈥媐iles/鈥媑uidance/鈥媐ile/鈥媠mq_鈥媔ntguide_鈥?7_鈥?_鈥媏nglish.鈥媝df . Accessed 3 Jun 2015.
  32.Brown EG. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Saf. 2002;25(6):445鈥?2.CrossRef PubMed
  33.Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14(7鈥?):343鈥?7.CrossRef PubMed
  34.Hauben M, Aronson JK. Defining 鈥榮ignal鈥?and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32(2):99鈥?10.CrossRef PubMed
  35.Kubota K, Koide D, Toshiki H. Comparison of data mining methodologies using Japanese spontaneous reports. Pharamcoepidemiol Drug Saf. 2004;13(6):307鈥?4.
  36.Maignon F, Hauben M, Hung E, VanHolle L, Dogne JM. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiol Drug Saf. 2014;23(2):195鈥?07.CrossRef
  37.Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R, Ball R, Hornbuckle K, Walsh L, Yee C, Sacks ST, Yuen N, Patadia V, Blum M, Johnston M, Gerrits C, Seifert H, Lacroix K. Perspectives on the use of data mining in pharmacovigilance. Drug Saf. 2005;28(11):981鈥?007.CrossRef PubMed
  38.EMEA Eudravigilance Expert Working Group (EV-EWG). Guideline on the use of statistical signal detection methods in the Eudravigilance data analysis system. 26 June 2008. London. Doc. Ref. EMEA/106464/2006 rev.1. http://鈥媤ww.鈥媏ma.鈥媏uropa.鈥媏u/鈥媎ocs/鈥媏n_鈥婫B/鈥媎ocument_鈥媗ibrary/鈥婻egulatory_鈥媋nd_鈥媝rocedural_鈥媑uideline/鈥?009/鈥?1/鈥媁C500011434.鈥媝df . Accessed 3 Jun 2015.
  39.Zhao J, Karlsson I, Asker L, Bostr枚m H. Applying methods for signal detection in spontaneous reports to electronic patient records. In: Proceedings of the ACM KDD; 2013.
  40.Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427鈥?6.CrossRef PubMed
  41.Nguyen TT, Dhond MR, Sabapathy R, Bommer WJ. Contrast microbubbles improve diagnostic yield in ICU patients with poor echocardiographic windows. Chest. 2001;120(4):1287鈥?2.CrossRef PubMed
  42.Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore. Drug Saf. 2007;30(8):645鈥?5.CrossRef PubMed
  43.Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ. 2006;333(7581):1267鈥?.PubMed Central CrossRef PubMed
  44.deBoissieu P, Kanagaratnam L, Abou Taam M, Roux MP, Drame M, Trenque T. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2014;23(9):989鈥?2.CrossRef
  45.Pariente A, Didailler M, Avillach P, Miremont-Salame G, Fourrier-Regalt A, Haramburu F, Moore N. A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf. 2010;19(11):1166鈥?1.CrossRef PubMed
  46.Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf. 2003;12(4):271鈥?1.CrossRef PubMed
  47.Hauben M, Reich L, DeMicco J, Kim K. 鈥淓xtreme duplication鈥?in the US FDA adverse events reporting system database. Drug Saf. 2007;30(6):551鈥?.CrossRef PubMed
  48.Bate A, Edwards IR. Data mining in spontaneous reports. Basic Clin Pharmacol Toxicol. 2006;98(3):324鈥?0.CrossRef PubMed
  49.Hauben M, Reich L, Gerrits CM, Younus M. Illusions of objectivity and recommendation for reporting data mining results. Eur J Clin Pharmacol. 2007;63(5):517鈥?1.CrossRef PubMed
  50.Schenker N, Gentleman JF. On judging the significance of differences by examining the overlap between confidence intervals. Am Stat. 2001;55(3):182鈥?.CrossRef
  51.Chen Y, Guo JJ, Healy DP, Lin X, Patel NC. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. Ann Pharmacother. 2008;42(12):1791鈥?.CrossRef PubMed
  52.Hauben M, Zou C, Whalen E, Wang W, Zhang LH. A pilot study on the feasibility of using P-plots for signal detection in pharmacovigilance. Stat Biopharm Res. 2015;7(1):25鈥?5.CrossRef
  53.Johnson K, Guo C, Gosink M, Wang V, Hauben M. Multinomial modeling and an evaluation of common data-mining algorithms for identifying signals of disproportionate reporting in pharmacovigilance databases. Bioinformatics. 2012;28(23):3123鈥?0.CrossRef PubMed
  54.Holmes S, Morris C, Tibshirani R. Bradley Efron: a conversation with good friends. Stat Sci. 2003;18(2):268鈥?2.CrossRef
  55.Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796鈥?03.PubMed Central CrossRef PubMed
  56.Candore G, Juhlin K, Manlik K, Thakrat B, Quarcoo N, Seabroke S, Wisniewski A, Slattery J. Comparison of statistical signal detection methods within and across spontaneous reporting system databases. Drug Saf. 2015;38(6):577鈥?7.CrossRef PubMed
  57.Ghosh P, Dewanji A. Effect of reporting bias in the analysis of spontaneous reporting data. Pharm Stat. 2015;14(1):20鈥?.CrossRef PubMed
  
• 作者单位：Manfred Hauben (1) (3)
  Eric Y. Hung (3)
  Kelly C. Hanretta (2)
  Sripal Bangalore (1)
  Vincenza Snow (3)
  
  1. New York University Medical Center, New York, NY, USA
  3. Pfizer, Incorporated, 219 East 42nd Street, New York, NY, 10017, USA
  2. Mount Sinai School of Medicine, New York, NY, USA
  
• 刊物主题：Drug Safety and Pharmacovigilance; Pharmacology/Toxicology;
• 出版者：Springer International Publishing
• ISSN：1179-1942

文摘

Introduction Perflutren microbubble/microsphere ultrasound contrast agents have a black-box warning based on case reports of serious cardiopulmonary events. There have been several subsequent observational safety studies. Large spontaneous reporting databases may help detect/refine signals of rare adverse events that elude other data sources/study designs.